Recida Therapeutics, Inc. — Form D
Recida Therapeutics, Inc. of MENLO PARK, CA, a company, filed a Form D exempt-offering notice with the SEC on 2018-07-12. The offering totals $10.7M, of which $5.7M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2018-07-12
- Form: D
- Accession: 0001746104-18-000003
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $10.7M
- Amount sold: $5.7M
- Remaining: $5.0M
- Investors: 1
- Date of first sale: 2018-06-29
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-316724
Issuer
- Name: Recida Therapeutics, Inc.
- CIK: 0001746104
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 70 WILLOW ROAD, MENLO PARK, CA, 94025
- Phone: 650-325-5156
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Yigong Ge | Director | Menlo Park, CA |
| Patrick Heron | Director | Philadelphia, PA |
| David Socks | Director | Menlo Park, CA |
| Yigong Ge | Executive Officer | Menlo Park, CA |
| Michael Savino | Executive Officer | Fenton, MO |
More